R

Remix Therapeutics

Biotech firm developing mRNA-degrading therapies

Director Clinical Pharmacology

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-timeWatertown, MA, USAIn-person

About the Job

Requirements

  • A PhD, PharmD, or MD with relevant training in clinical pharmacology, pharmaceutical sciences, or a related discipline.
  • At least 10 years of clinical pharmacology experience in the biotech or pharmaceutical industry, including oncology and clinical-stage development.
  • Demonstrated expertise in clinical pharmacology strategy and study design from early development through registration.
  • Direct experience contributing to an NDA/MAA submission, including authoring clinical pharmacology sections of the filing.
  • Deep understanding of pharmacokinetic/pharmacodynamic principles, modeling and simulation, and exposure–response analysis.
  • Proven cross-functional leadership and ability to integrate complex scientific data into strategic development decisions.
  • Ability to present to senior leadership and external stakeholders.

Responsibilities

  • Lead the integrated clinical pharmacology strategy for REM-422, with primary responsibility for supporting late-stage development and potential regulatory submissions.
  • Drive dose optimization for REM-422 consistent with FDA Project Optimus expectations, including population pharmacokinetics, exposure–response, and model-informed drug development analyses.
  • Design and oversee clinical pharmacology studies evaluating food effect, drug–drug interactions, absorption and metabolism, and other intrinsic and extrinsic factors affecting REM-422 exposure.
  • Represent Clinical Pharmacology in regulatory interactions and lead relevant components of briefing documents and regulatory submissions.
  • Provide clinical pharmacology leadership for emerging pipeline programs, translating nonclinical pharmacology, ADME, pharmacokinetics, and toxicology data into integrated IND-enabling and early clinical development strategies.
  • Support human pharmacokinetic projections, first-in-human dose selection, dose-escalation design, pharmacokinetic/pharmacodynamic assessments, and early identification of clinical pharmacology risks.
  • Partner cross-functionally and oversee external vendors to ensure high-quality, timely delivery of studies, analyses, models, and regulatory documentation.

About the Company

Remix Therapeutics

Biotech firm developing mRNA-degrading therapies

Remix Therapeutics develops medicines for rare diseases by using targeted degradation of mRNA with an oral small molecule. Its lead candidate REM 422 degrades messenger RNA to stop production of disease-causing proteins and is in Phase 1 trials for ACC and AML, with FDA Orphan Drug designation. The company funds R&D through grants, partnerships, and eventual commercialization, leveraging collaborations with larger pharma. Its goal is to deliver safe and effective medicines for rare cancers and genetic disorders by advancing REM 422 and expanding its portfolio to address unmet medical needs.

Company size
51-200
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2018

Recently Posted Jobs

Explore more opportunities at Remix Therapeutics

See more jobs